Blood-Based Biomarker Panel for Early AD Detection

V2, Crosslink

🧫

Blood-Based Biomarker Panel for Early AD Detection

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-blood-bi

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Blood-Based Biomarker Panel for Early AD Detection ## Background and Rationale Alzheimer's disease (AD) diagnosis currently relies on costly neuroimaging and invasive cerebrospinal fluid analysis, limiting early detection capabilities. This study addresses the critical need for accessible, blood-based biomarkers that can identify AD pathology before clinical symptoms manifest. The experiment leverages a multi-analyte approach, measuring established AD biomarkers including amyloid-β peptides (A

METHODOLOGY NOTES

Phase 1: Recruit 300 participants (100 cognitively normal controls, 100 MCI, 100 early AD) with confirmed amyloid PET status. Collect 10ml EDTA blood samples following 12-hour fasting. Phase 2: Process samples within 2 hours using standardized protocols. Separate plasma via centrifugation (2000g, 10 minutes, 4°C) and store at -80°C. Phase 3: Perform multiplex immunoassays using Simoa HD-X analyzer for Aβ40, Aβ42, p-tau181, p-tau217, NfL, and GFAP. Conduct ELISA for inflammatory markers (IL-6, TNF-α, CRP) and LC-MS/MS for metabolomic profiling. Phase 4: Culture SH-SY5Y cells and treat with 1μM Aβ42 oligomers for 24-48 hours. Collect conditioned media and measure biomarker release using identical assays. Phase 5: Apply machine learning algorithms (random forest, support vector machines, neural networks) to integrate biomarker data. Use 70% of samples for training, 30% for validation with 10-fold cross-validation. Phase 6: Develop composite diagnostic score and establish optimal cut-off v

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.902371Z'}
summary	# Blood-Based Biomarker Panel for Early AD Detection ## Background and Rationale Alzheimer's disease (AD) diagnosis currently relies on costly neuroimaging and invasive cerebrospinal fluid analysis, l
entities	{'genes': ['ABCB1/APOE/CAV1'], 'diseases': ["Alzheimer's Disease"]}
model_system	cell_line
_schema_version	1
experiment_type	clinical
primary_outcome	Diagnostic accuracy (sensitivity and specificity ≥85%) of the blood biomarker panel for detecting Aβ-positive individuals compared to amyloid PET imaging as the gold standard.
methodology_notes	Phase 1: Recruit 300 participants (100 cognitively normal controls, 100 MCI, 100 early AD) with confirmed amyloid PET status. Collect 10ml EDTA blood samples following 12-hour fasting. Phase 2: Proces
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.902376', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

633

Outgoing

544

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Blood-Based Biomarker Panel for Early AD Detection

derives from (16)

supports (109)

💬 Discussion